Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- -
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
- Conditions
- Interventions
- Drug: AbirateroneDrug: ApalutamideProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyDrug: DarolutamideDrug: DegarelixDrug: EnzalutamideDrug: GoserelinDrug: HistrelinDrug: LeuprolideProcedure: Magnetic Resonance ImagingOther: Patient ObservationProcedure: Positron Emission TomographyDrug: PrednisoneOther: Questionnaire AdministrationDrug: RelugolixRadiation: Stereotactic Body Radiation TherapyDrug: Triptorelin
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06378866
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Cardiometabolic Consequences of the Loss of Ovarian Function
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 100
- Registration Number
- NCT06264882
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT06218667
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05917860
- Locations
- 🇫🇮
Turku University Hospital, Turku, Southwest Finland, Finland
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05873192
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Brown University
- Target Recruit Count
- 32
- Registration Number
- NCT05839119
- Locations
- 🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Praful Ravi, MB BCHir, MRCP
- Target Recruit Count
- 9
- Registration Number
- NCT05617885
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ETHAN - ET for Male BC
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jose Pablo Leone
- Target Recruit Count
- 60
- Registration Number
- NCT05501704
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.